The recognition of TK dysregulation as a key driver in NSCLC has led to the development of tyrosine kinase inhibitors (TKIs), which have significantly improved patient outcomes, particularly in cases with EGFR mutations. The gene discussed is TKT; the disease is non-small cell lung carcinoma.